Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM1005 in healthy volunteers
NCT06640647Phase 1Completed
- Sponsor
- Huadong Medicine
- Start
- Mar 2024
- Primary completion
- Aug 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of poterepatide in obesity (7 cohorts), sponsored by Huadong Medicine. Primary endpoint: Safety Outcomes at 29 days. Started Mar 2024; status: completed.
02
Drugs
poterepatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06640647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06640647.